ETV + ADV | TDF | TDF + ETV | |
---|---|---|---|
N | 25 | 27 | 20 |
Age, years | 43 (21–64) | 44 (20–64) | 46 (30–68) |
Male, n (%) | 20, 80.00% | 23, 85.19% | 13, 65% |
ALT (IU/L) | 120.46 | 61.12 | 71.00 |
Normal ALT, n (%) | 13, 52.00% | 17, 62.96% | 10, 50.00% |
Bilirubin, mg/dL | 18.93 | 20.67 | 33.86 |
Creatinine, mg/dL | 78.97 | 90.62 | 75.43 |
HBeAg-positivity, n (%) | 17, 67.00% | 23, 85.19% | 15, 75.00% |
HBV DNA (log10 IU/mL) | 6.31 | 5.40 | 6.23 |
Previously exposed NUC, n | |||
LMV | 23 | 14 | 14 |
ADV | 0 | 6 | 3 |
LDT | 1 | 2 | 1 |
LMV + ADV | 1 | 5 | 2 |
Duration of NUC treatments (months) | 28 (6–110) | 26 (6–64) | 26 (6–72) |
Resistance mutations | |||
ETV | 18 | 22 | 17 |
Multidrug resistance | 7 | 5 | 3 |